The company plans to utilize its proprietary C1 gene expression platform to accelerate the development, lower production costs and improve the performance of biologic vaccines and drugs.
"We are very excited to enter into this collaboration with another top-five pharmaceutical company to demonstrate the potential of C1 to become a platform of choice for manufacturing certain protein-based biologics,” Dyadic CEO Mark Emalfarb said in a statement.
“We have been selected for this collaboration because of the attributes of our C1 technology which include, speed of development, high productivity, low cost of goods, among other properties.”
READ: Dyadic collaborates with leading global animal health companies to demonstrate its C1 platform to treat farm animal diseases
Dyadic expects to produce two different types of therapeutic compounds as part of the collaboration, the CEO noted.
"Over the past year, we have dedicated our expertise and financial resources to further enhance our core C1 technology and have made significant progress reducing background protease activity and developing a library of differentiated strains, including glycoengineered strains, which we continue to refine,” Emalfarb said.
“Additionally, we have been able to demonstrate the broad applications of our C1 technology, which in turn has resulted in many new wide-ranging opportunities, Dyadic's pipeline of opportunities with top tier, global animal and human health pharmaceutical companies continues to get larger and more diverse as the C1 technology becomes more widely applicable," he added.
Contact Andrew Kessel at [email protected]
Follow him on Twitter @andrew_kessel